Key points are not available for this paper at this time.
Aim and Objectives: The aim of the study is assess the safety profile and efficacy of salmeterol and Tiotropium in patients with COPD. The objective is to compare to evaluate the safety profile and efficacy of salmeterol and Tiotropium in patients with COPD. Methodology: This was a prospective observational study conducted at secondary care hospital in India. In our study, we have included a total of 50 patients who are divided in to two groups based on their treatment and follow-ups was done for 12 weeks. Results: Patients were divided into 2 equal groups to receive salmeterol and Tiotropium (25 subjects each). The mean FEV1 level at baseline was 63.72±3.0210 for Tiotropium group and 64.96±1.645 for Salmeterol group and the mean FEV1 level after 12 weeks of treatment was 72.12±1.423 for Tiotropium group and 70.68±1.973 for Salmeterol group. Tiotropium treatment were associated with significant decrease in FEV1 level from baseline to 12 weeks. (P*<0.05). Conclusion: In our study, by performing the study, we concluded that tiotropium used once daily, produced superior bronchodilation and reduced dyspnea in patients with COPD when compared with salmeterol. Patients treated with tiotropium also indicated more improvement in their symptoms than those who treated with salmeterol. Because of these advantages, tiotropium should be considered first-line treatment in patients with COPD. While performing the safety parameters for a drug, side effects of tiotropium are less when compared to salmeterol.
Jagadeesh et al. (Fri,) studied this question.